BACKGROUND Breast carcinoma is the most common malignant tumour and the leading cause of death in women. Various prognostic and predictive factors are used in the management of breast cancer. Oestrogen receptor (ER), progesterone receptor (PR) & human epidermal growth receptor (HER2/neu) are prognostic as well as predictive factors. The aim of the present study was conducted to evaluate ER, PR & HER2/neu expression in invasive ductal carcinoma of the breast (not otherwise specified) by immunohistochemistry to explore the correlation of these markers to each other, as well as to various clinicopathological parameters like age of patient, histological grade, tumour size and lymph node metastasis. MATERIALS AND METHODS 100 cases of infiltrating ductal carcinoma (NOS) were taken. Slides were prepared from paraffin blocks containing cancer tissue of these patients & immunohistochemical staining was done for ER, PR, and HER2/neu expressions. Interpretation of expressions done using Allred scoring system for ER/PR & ASCO/CAP guidelines for HER2/neu. Statistical analysis was done to determine the statistical significance by applying chi-square test. RESULTS In our study, mean age was 55.28 years. Average tumour size was 4.3 cm & majority of tumours were grade II. 38 patients had axillary lymph nodes positive for metastasis. 58 cases were both ER & PR positive and 37 cases ER/PR negative. Only 7 were HER2/neu positive & 93 were HER2/neu negative. Only 2 cases were both ER as well as HER2/neu positive, 32 cases were both ER & HER2/neu negative. 66 cases showed different expressions of ER & HER/neu. ER & PR correlated significantly with age, tumour size, and tumour grade; whereas HER2/neu correlated significantly with age & tumour size only. No association was seen with axillary lymph node metastasis. ER and PR expression correlated with each other, but none was correlated with HER2/neu. CONCLUSION Assessment of hormone receptors for clinical management of a breast cancer patient is strongly recommended to provide prognostic information and therapeutic options.